Breast Cancer: Current Insights into Epidemiology, Molecular Mechanisms, and Therapeutic Approaches

[*1]Sonlimar Mangunsong, [2]Aninditha Rachmah Rachmadhini and [3]Sarmalina Simamora
Palembang Health Polytechnic, Pharmacy Department
[*]sonlimar@poltekkespalembang.ac.id

Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women worldwide. Despite significant advancements in molecular understanding and the development of targeted therapies, the management of this disease remains challenging, particularly in low-resource settings. This article reviews the global and regional epidemiology of breast cancer, highlighting its increasing incidence and the disparities in outcomes between high- and low-income countries. It also examines the molecular mechanisms underlying tumor growth, focusing on genetic mutations, hormone receptor status, and HER2 expression. Furthermore, the article explores innovative therapeutic strategies, including targeted therapies, immunotherapy, and combination treatments, which offer promising results for improving patient outcomes. The role of predictive tools, such as Oncotype DX and Mammaprint, in personalizing treatment strategies is also discussed. By examining tumor heterogeneity, biomarker-based approaches, and advances in early detection, this research aims to provide a comprehensive perspective on the evolving landscape of breast cancer management and the potential for more effective and individualized therapies.

Keyword: Breast Cancer, Chemotherapy , Systematic Review , Molecular Mechanism

INTRODUCTION

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related mortality among women worldwide. According to the Global Cancer Observatory (GLOBOCAN) 2020 report, breast cancer accounts for approximately 11.7% of all new cancer cases globally, with an estimated 2.3 million new diagnoses and 685,000 deaths annually (Sung et al., 2021). The increasing incidence of breast cancer is closely linked to factors such as population growth, aging, and changes in lifestyle, including physical inactivity, unhealthy diets, and rising obesity rates (World Health Organization, 2021). These trends underscore the growing burden of the disease, which requires urgent attention from both global health organizations and local healthcare providers (Wilkinson and Gathani, 2021).

Regionally, the incidence and mortality rates of breast cancer vary significantly between high-income and low- to middle-income countries. In high-income regions such as North America and Europe, the incidence of breast cancer is relatively high, largely due to widespread access to early screening programs, advanced diagnostic tools, and comprehensive healthcare systems. These regions benefit from improved survival outcomes because of better access to early detection, effective treatment, and supportive care. For example, in countries like the United States, the five-year survival rate for breast cancer exceeds 90%, primarily due to early diagnosis

through regular screenings like mammograms, as well as advancements in treatments such as targeted therapies and immunotherapy (Bray et al., 2018; Kashyap et al., 2022)..

However, in low- and middle-income countries, especially in parts of Asia and Africa, the picture is less optimistic. Although breast cancer incidence rates are rising in these regions, mortality rates remain disproportionately high. This is due to several factors, including limited access to healthcare, late-stage diagnosis, and a lack of public awareness regarding breast cancer symptoms and risk factors. In Southeast Asia, for instance, breast cancer has become the leading cause of cancer-related deaths among women, with countries like Indonesia reporting an alarming increase in both incidence and mortality over the past decade (Azamjah, Soltan-Zadeh & Zayeri, 2019). In many of these regions, cultural barriers, lack of screening programs, and inadequate healthcare infrastructure contribute to late-stage diagnoses and poor prognosis.

These global and regional disparities in breast cancer epidemiology highlight the need for targeted interventions. There is a growing recognition that addressing these disparities requires not only improvements in early detection and screening programs but also raising public awareness about the importance of self-examination, risk factors, and timely medical consultation. In addition, equitable access to treatment options, including surgery, chemotherapy, and newer therapies like targeted treatments and immunotherapy, is crucial to improving outcomes and reducing the global burden of breast cancer (Sung et al., 2021).

Furthermore, breast cancer is a heterogeneous disease, meaning it consists of various molecular subtypes with distinct characteristics, behaviors, and treatment responses. The molecular understanding of breast cancer has evolved significantly, enabling the identification of biomarkers such as estrogen receptors (ER), progesterone receptors (PR), and HER2, which help to classify the disease into distinct subtypes. These molecular distinctions not only provide valuable information for prognosis but also guide clinicians in choosing the most appropriate treatment strategies, such as hormone therapy, HER2-targeted therapies, or chemotherapy (Turner & Reis-Filho, 2012).

The study of molecular mechanisms and the development of innovative therapies play a central role in improving the prognosis of breast cancer patients. Unlike traditional treatments that affect both healthy and cancerous cells, newer approaches focus on targeting specific molecular pathways involved in cancer progression, offering more precise and less toxic treatment options. For instance, targeted therapies like trastuzumab for HER2-positive cancers and endocrine therapies for hormone receptor-positive breast cancer have significantly improved survival rates for patients with these subtypes. Similarly, the advent of immunotherapy has opened new avenues for treating aggressive forms of breast cancer, such as triple-negative breast cancer (TNBC), which has limited treatment options and a poorer prognosis (Tsang and Tse, 2020; Zhang et al., 2020).

In this context, understanding the underlying biology of breast cancer, including genetic mutations, epigenetic changes, and the role of key molecular pathways, is crucial for developing effective and personalized treatment strategies. This article will explore the epidemiology, molecular mechanisms, and innovative therapeutic approaches in breast cancer, with a particular

focus on targeted therapies, immunotherapy, and the importance of early detection methods such as genomic tests and imaging techniques. By advancing our understanding of breast cancer at both the molecular and clinical levels, we can improve patient outcomes and reduce the global burden of this disease.

METHODS

This article utilizes a systematic literature review approach to analyze recent research on the epidemiology, molecular mechanisms, tumor subtypes, and therapeutic advancements in breast cancer. The literature search was conducted using a combination of electronic databases, including PubMed, Scopus, and Google Scholar, with a focus on studies published within the last five years to ensure the inclusion of the most up-to-date information. Key terms used in the search included "breast cancer epidemiology," "molecular mechanisms," "biomarkers," "tumor heterogeneity," "targeted therapies," and "immunotherapy."

The review examined data from global health organizations, particularly GLOBOCAN (2020), which provides global cancer statistics, and the World Health Organization (WHO) reports on breast cancer prevention, diagnosis, and treatment (World Health Organization, 2021). In addition to epidemiological data, studies from contemporary oncology textbooks were consulted to provide a broad understanding of the current therapeutic landscape, including surgical, radiotherapy, chemotherapy, and novel molecular-based therapies.

A detailed analysis was conducted on the molecular biology of breast cancer, particularly focusing on genetic mutations (e.g**.,** BRCA1**,** BRCA2**),** the role of hormonal receptors (e.g**.,** ER**,** PR,
(e.g., trastuzumab, CDK inhibitors), immunotherapy**,** and combination therapies, was critically evaluated for their efficacy in different breast cancer subtypes such as hormone receptor-positive, HER2-positive, and triple-negative breast cancer (TNBC).

Inclusion criteria for studies were based on relevance to breast cancer treatment and molecular profiling, clinical trials assessing therapeutic efficacy, and publications focused on global epidemiological trends. Exclusion criteria included studies that were outdated, lacked sufficient clinical data, or did not provide molecular insights into breast cancer.

The synthesis of the selected studies was aimed at providing a comprehensive overview of the current understanding of breast cancer's pathophysiology and treatment options, as well as highlighting gaps in research that could benefit from further exploration.

RESULTS

Breast cancer is known for its significant molecular heterogeneity, meaning that even within a single tumor, there are various populations of cancer cells with distinct genetic and phenotypic features. This heterogeneity directly influences tumor behavior, including how it grows, spreads (metastasizes), and responds to treatment. The identification of different molecular subtypes of breast cancer has been a major breakthrough in understanding the disease and improving clinical

outcomes (Roy et al., 2023). These subtypes, based on the presence of specific molecular markers such as hormone receptors (ER, PR) and HER2, have distinct characteristics in terms of aggressiveness, prognosis, and response to treatment.

Molecular Subtypes and Their Characteristics

1. **Luminal A**
   - Characteristics: Luminal A is characterized by the presence of estrogen receptors (ER-positive) and progesterone receptors (PR-positive)**,** with HER2-negative status. These tumors generally have a lower Ki-67 index, indicating slower cell proliferation.
   - Prognosis: Luminal A tumors typically have the best prognosis, as they tend to grow more slowly and are highly responsive to hormone therapies that block estrogen or its receptor (e.g., tamoxifen, aromatase inhibitors).
   - Treatment: Hormone therapy is the cornerstone of treatment for Luminal A breast cancer. Chemotherapy is generally avoided unless there are signs of high-risk features, such as lymph node involvement.
2. **Luminal B**
   - Characteristics: Similar to Luminal A, Luminal B tumors are ER-positive and PR-positive, but they can be either HER2-negative or HER2-positive and have a higher Ki-67 index, which reflects a higher rate of cell proliferation.
   - Prognosis: These tumors tend to have a worse prognosis compared to Luminal A due to their faster growth rate and higher likelihood of metastasis.
   - Treatment**:** While endocrine therapy remains the foundation of treatment, chemotherapy is often used in addition to hormone therapy, especially for HER2-positive cases. HER2-targeted therapies like trastuzumab (Herceptin) may also be used if the tumor overexpresses HER2.
3. **HER2-enriched**
   - Characteristics: HER2-enriched tumors are defined by HER2 overexpression (HER2-positive) and are typically ER-negative and PR-negative**.** These tumors tend to be more aggressive and have a higher rate of cell division.
   - Prognosis: HER2-positive tumors are considered more aggressive but have a better prognosis with the advent of targeted therapies aimed at HER2.
   - Treatment**:** HER2-targeted therapies, such as trastuzumab (Herceptin) and pertuzumab, significantly improve outcomes in HER2-positive breast cancer by inhibiting HER2 signaling, which drives cancer cell proliferation. Chemotherapy is often combined with these therapies to enhance treatment efficacy (Barzaman et al., 2020).
4. **Triple-negative breast cancer (TNBC)**
   - Characteristics: TNBC is defined by the absence of ER**,** PR**,** and HER2 expression, making it resistant to the common hormonal therapies and HER2-targeted therapies that are effective for other subtypes.
   - Prognosis: TNBC is often more aggressive and has a poorer prognosis due to its lack of targeted treatment options. It also has a higher likelihood of recurrence, particularly within the first few years following treatment.
   - Treatment**:** Chemotherapy remains the main treatment option for TNBC. However, newer therapies like immunotherapy and PARP inhibitors have shown promising

results, particularly in patients with BRCA mutations. Immunotherapies such as checkpoint inhibitors (e.g., pembrolizumab) are being explored to enhance the immune system's ability to recognize and destroy cancer cells.

Impact of Predictive Tools: Oncotype DX and Mammaprint

The use of predictive genomic tools such as Oncotype DX and Mammaprint has revolutionized the way breast cancer is treated, particularly by enabling more personalized treatment plans. These tools provide valuable insights into the likelihood of cancer recurrence and help guide decisions on whether chemotherapy is necessary, especially in early-stage cancers.

1. **Oncotype DX**
   - Test Process**:** Oncotype DX analyzes the expression of 21 genes in a tumor sample, generating a recurrence score that predicts the risk of recurrence in hormone receptor-positive**,** HER2-negative breast cancer.
   - Recurrence Score: The recurrence score ranges from 0 to 100. A low score (less than 18) indicates a low risk of recurrence, suggesting that chemotherapy may not be necessary, and patients can be treated effectively with hormone therapy alone. A high **score** (greater than 30) suggests a high risk of recurrence, warranting the addition of chemotherapy to the treatment regimen. Intermediate scores (18–30) require further consideration based on other clinical factors.
   - Clinical Impact: Oncotype DX has significantly reduced the use of unnecessary chemotherapy, sparing patients with low recurrence risk from the toxicities associated with chemotherapy, thereby improving their quality of life without compromising survival outcomes (Paik et al., 2004).
2. **Mammaprint**
   - Test Process: Mammaprint is a multigene test that evaluates the expression of 70 genes, providing a risk assessment for distant metastasis within five to ten years after diagnosis. It categorizes patients as having low risk or high risk for recurrence.
   - Clinical Impact**:** Like Oncotype DX, Mammaprint is used to guide decisions regarding chemotherapy, particularly in early-stage, hormone receptor-positive, HER2-negative breast cancers. For high-risk patients**,** chemotherapy is often recommended, whereas low-risk patients may avoid chemotherapy, opting for hormone therapy alone (MammaPrint, 2020).
   - Global Adoption: Mammaprint has been adopted in several international guidelines as a tool to assist in treatment decisions, especially in regions where overuse of chemotherapy is a concern (van’t Veer et al., 2002).

Molecular-Targeted Therapies and Immunotherapy

The development of molecular-targeted therapies has dramatically improved the treatment of specific breast cancer subtypes. For instance, the introduction of HER2-targeted therapies, such as trastuzumab (Herceptin), has significantly increased survival rates in HER2-positive breast cancer**.** These therapies specifically target and block the HER2 receptor, which is overexpressed in some breast cancers, preventing cancer cells from proliferating.

Additionally, immunotherapy **i**s showing promise in treating aggressive subtypes such as **TNBC**, which previously lacked targeted treatment options. Recent clinical trials have demonstrated the efficacy of immune checkpoint inhibitors in improving outcomes for TNBC patients, particularly those with *PD-L1-positive tumors* (Schmid et al., 2018).

DISCUSSION

Breast cancer is a multifaceted disease, marked by considerable molecular heterogeneity that significantly influences treatment outcomes and patient prognosis. The classification of breast cancer into distinct molecular subtypes—Luminal A**,** Luminal B**,** HER2-enriched, and Triple-negative breast cancer (TNBC)**—**has provided invaluable insights into tumor biology and therapeutic strategies. This molecular understanding has led to personalized treatment approaches, which are crucial for improving survival rates and minimizing unnecessary side effects, particularly in low-risk patients.

Molecular Heterogeneity and Its Clinical Implications

As highlighted in the results, the molecular heterogeneity of breast cancer is one of the primary challenges in managing the disease. Each molecular subtype exhibits unique genetic and biological characteristics that influence the tumor's behavior, aggressiveness, and response to treatment. For example, Luminal A cancers, which are ER-positive**,** PR-positive**,** and HER2-negative**,** generally have a more indolent course and respond well to hormonal therapies. This subtype's favorable prognosis is linked to its slower growth rate, which allows for a more targeted approach, focusing primarily on hormone therapy, with limited use of chemotherapy unless there are additional risk factors, such as lymph node involvement (Li et al., 2022; Sung et al., 2021).

On the other hand, Luminal B cancers are characterized by higher proliferation rates, as indicated by a higher Ki-67 index. While these tumors remain ER-positive and PR-positive, their higher risk of recurrence necessitates the use of both endocrine therapy and chemotherapy. Moreover, HER2-enriched tumors, defined by HER2 overexpression, have shown significant improvement in survival due to the introduction **of** HER2-targeted therapies like trastuzumab. These treatments specifically target and block the HER2 receptor, preventing cancer cells from proliferating. As a result, HER2-positive breast cancers have become one of the most treatable forms of the disease, thanks to the precision of these therapies (Slamon et al., 2001; Katsura et al., 2022).

However, the most challenging subtype remains Triple-negative breast cancer (TNBC)**,** which lacks ER**,** PR**,** and HER2 expression. This absence of molecular targets makes TNBC resistant to conventional hormonal therapies and HER2-targeted treatments. As a result, chemotherapy has remained the cornerstone of treatment, although TNBC's aggressive nature and high recurrence rates highlight the urgent need for novel therapies. Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab, is showing promise in improving outcomes for TNBC patients, especially those with PD-L1-positive tumors (Schmid et al., 2018). This represents a

significant shift in treatment paradigms, moving from cytotoxic chemotherapy to therapies that enhance the immune system's ability to fight cancer.

Impact of Predictive Tools in Personalized Treatment

The use of genomic tests like Oncotype DX and Mammaprint has revolutionized the treatment of breast cancer by allowing for a more personalized approach to therapy. These predictive tools assess the genetic activity within a tumor, generating risk scores that help determine the likelihood of cancer recurrence and whether chemotherapy is necessary. In the case of Oncotype DX**,** the recurrence score provides essential information for hormone receptor-positive, HER**2-**negative breast cancer patients, guiding decisions regarding the need for chemotherapy. Patients with low recurrence scores can avoid unnecessary chemotherapy, reducing treatment-related toxicity and improving quality of life, while those with high scores can receive more aggressive treatment, including chemotherapy, to address the higher risk of recurrence (Paik et al., 2004).

Similarly, Mammaprint**,** which evaluates the expression of 70 genes associated with tumor proliferation and metastasis, stratifies patients into high and low-risk categories. This test, particularly useful for early-stage, hormone receptor-positive, HER2-negative cancers, helps to avoid overtreatment in low-risk patients while ensuring that high-risk patients receive appropriate chemotherapy. Both tests have significantly contributed to reducing overtreatment and undertreatment, leading to better outcomes for patients across different risk profiles. The growing use of these tests in clinical practice exemplifies the shift towards precision medicine in breast cancer care, where treatment is tailored based on the genetic makeup of both the tumor and the patient (MammaPrint, 2020).

Molecular-Targeted Therapies and Immunotherapy: Progress and Challenges

Molecular-targeted therapies have dramatically changed the treatment landscape for various subtypes of breast cancer. The introduction of targeted agents, such as trastuzumab for HER2-positive tumors and aromatase inhibitors for ER-positive tumors, has improved survival rates and reduced relapse. However, despite the success of HER2-targeted therapies, resistance mechanisms remain a major challenge. Resistance to trastuzumab, for example, often develops due to alterations in the PI3K/AKT/mTOR signaling pathway, which can bypass HER2 inhibition and drive tumor progression (Turner & Reis-Filho, 2012).

In TNBC**,** the lack of targeted therapies has led to a focus on immunotherapy **as** a promising treatment option. Immunotherapy **a**ims to harness the body's immune system to recognize and eliminate cancer cells. For TNBC, immune checkpoint inhibitors such as pembrolizumab and atezolizumab have shown efficacy, particularly in tumors expressing PD-L1**.** However, while these therapies represent a significant advancement, challenges remain in identifying the patient population that will benefit the most. Ongoing research is focused on refining biomarkers to predict response to immunotherapy and developing combination therapies that can increase the effectiveness of immunotherapy (Zhang et al., 2020).

Furthermore, the development of combination therapies—which combine targeted therapies, immunotherapy, and chemotherapy—holds promise for overcoming drug resistance and addressing the complex nature of breast cancer. For example, combining HER2-targeted therapies with chemotherapy has proven effective in HER2-positive breast cancer, and the addition of checkpoint inhibitors to chemotherapy regimens for TNBC may enhance therapeutic efficacy. However, the challenge lies in balancing toxicity**,** cost**,** and patient tolerability, particularly in patients who may require long-term treatment.

Global Disparities and the Need for Equitable Access

While significant progress has been made in breast cancer treatment, global disparities remain, especially between high-income and low- to middle-income countries. Access to the latest targeted therapies and predictive tests like Oncotype DX and Mammaprint is limited in many low-resource settings. This gap results in late-stage diagnoses**,** suboptimal treatment options, and ultimately higher mortality rates in these regions. Addressing these disparities requires global health initiatives focused on improving access to screening, education, and advanced treatments. Equitable access to care should be a priority, with targeted interventions aimed at reducing the burden of breast cancer in underserved populations (Bray et al., 2018).

CONCLUSION

Breast cancer continues to be a major global health concern, with its increasing incidence and impact on women's health worldwide. Despite substantial advancements in molecular understanding and therapeutic strategies, including targeted therapies and immunotherapy, challenges remain in managing this disease, especially in low-resource settings. The molecular heterogeneity of breast cancer necessitates personalized treatment approaches, where tools like Oncotype DX and Mammaprint are increasingly crucial for tailoring therapy to individual patient profiles, thereby improving outcomes while minimizing unnecessary treatments.

Innovations in targeted therapies**,** such as HER2-targeted treatments for HER2-positive breast cancer, and the emerging role **of** immunotherapy for aggressive subtypes like Triple-negative breast cancer (TNBC**)**, offer hope for more effective treatments. However, the challenge of drug resistance, particularly in TNBC, and the need for global access to these therapies remain significant obstacles.

Further research into the molecular mechanisms of breast cancer, coupled with advancements in early detection, will continue to enhance the ability to treat the disease more effectively. Moving forward, a concerted global effort is required to address healthcare disparities, ensure equitable access to advanced treatments, and improve survival rates, particularly in under-resourced areas.

Conflict of interest: Authors declare there is no conflict of interest.

REFERENCES

1. Azamjah, N., Soltan-Zadeh, Y., & Zayeri, F. (2019). Global trend of breast cancer mortality rate: A 25-year study. *Asian Pacific Journal of Cancer Prevention, 20*(7), 2015–2020.
2. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020 Jul;84:106535. doi: 10.1016/j.intimp.2020.106535. Epub 2020 Apr 29. PMID: 32361569.
3. Bray, F., Ferlay, J., Soerjomataram, I., Laversanne, M., & Jemal, A. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 71*(3), 209–249.
4. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 68*(6), 394–424.
5. Cardoso, F., Costa, A., Senkus, E., et al. (2017). 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Annals of Oncology, 28*(1), 16–33.
6. El Sayed, R., & Dalmia, A. (2020). Targeting immune checkpoints in breast cancer. *Clinical Cancer Research, 26*(7), 1767-1779.
7. Gauthier, J., & Litton, J.K. (2018). Triple-negative breast cancer: A review of the molecular subtypes and clinical management. *Journal of Clinical Oncology, 36*(6), 561–571.
8. Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. Biomed Res Int. 2022 Apr 18;2022:9605439. doi: 10.1155/2022/9605439. Retraction in: Biomed Res Int. 2023 Dec 29;2023:9872034. doi: 10.1155/2023/9872034. PMID: 35480139; PMCID: PMC9038417.
9. Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7. doi: 10.12968/hmed.2021.0459. Epub 2022 Feb 7. PMID: 35243878.
10. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022 Jan 26;16:305-314. doi: 10.2147/DDDT.S336643. PMID: 35115765; PMCID: PMC8801368.
11. MammaPrint® (2020). *Mammaprint®: Risk Assessment for Breast Cancer*. [online] Available at: https://www.agendia.com/mammaprint/.
12. Morrow, M., & Schnitt, S.J. (2018). The role of surgery in the treatment of breast cancer. *Cancer*, *124*(1), 5-12.
13. Nichols, K., & Goetz, M.P. (2018). Targeted therapies in the management of HER2-positive breast cancer. *Seminars in Oncology Nursing, 34*(4), 345–354.
14. Paik, S., Shak, S., Tang, G., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *New England Journal of Medicine*, 351(27), 2817-2826.
15. Reeder-Hayes, K.E., & Liu, M. (2020). Clinical advances in breast cancer. *Journal of Clinical Oncology, 38*(16), 1831–1845.
16. Roy M, Fowler AM, Ulaner GA, Mahajan A. Molecular Classification of Breast Cancer. PET Clin. 2023 Oct;18(4):441-458. doi: 10.1016/j.cpet.2023.04.002. Epub 2023 May 31. PMID: 37268505.

17. Schmid, P., Adams, S., Rugo, H.S., et al. (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*, 379, 2108–2121.
18. Slamon, D.J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *New England Journal of Medicine*, 344(11), 783-792.
19. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 71*(3), 209–249.
20. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020 Jan;27(1):27-35. doi: 10.1097/PAP.0000000000000232. PMID: 31045583.
21. Turner, N.C., & Reis-Filho, J.S. (2012). Genetic heterogeneity and breast cancer therapy. *Nature Reviews Cancer*, 12(11), 745-756.
22. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID: 34905391; PMCID: PMC8822551.
23. Zhang, L., Wang, L., & Wang, Z. (2020). Immunotherapy for breast cancer: Current status and future directions. *Journal of Clinical Medicine*, 9(8), 2668.